IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) announced on Wednesday that Focus Medical Herbs Ltd. completed the importation of approximately 399 kilograms of Canadian premium indoor grown dried cannabis from Trichome JWC Acquisition Corp., its wholly-owned Canadian cultivation subsidiary and an additional supply partner.
The launch of the product in the Israeli medical cannabis market by Focus Medical is expected by the end of the first quarter of 2022.
The Company expects Focus Medical to import additional quantities of premium dried cannabis from TJAC, as well as its supply partners in Canada and elsewhere, on a steady basis in the future.
the medical cannabis imported from TJAC will be sold to Israeli patients under license under the WAGNERS brand, the company’s popular Canadian recreational brand, and WAGNERS Premium, indoor dried flower.
Oren Shuster, CEO of IM Cannabis called this decision an important milestone in the company’s strategic objectives.
“Israel’s medical cannabis market is changing rapidly and demands only the best premium cannabis,” Shuster said. “With our globally integrated supply chain, indoor cultivation in Canada, and a coordinated team of compliance, regulatory and procurement professionals, our company is uniquely positioned to meet the needs of patients and customers in Israel, Canada and Germany.”
More recent news from IM Cannabis:
Flow Corp. makes its debut in the Israeli cannabis market with its first delivery of marijuana
Canadian cannabis lands in Germany: IMCC takes the Wagners brand across the pond
IM Cannabis to buy Jerusalem-based medical marijuana pharmacy for $4.9 million in cash and stock
IM Cannabis to launch WAGNERS brand in Israel after receiving regulatory approval
IMCC Price Action
IM Cannabis’ shares traded down 3.41% at $2.5501 per share at the time of writing Wednesday.
Photo: Courtesy of Tim Foster on Unsplash
